Phio Pharmaceuticals Corp. · Drugmakers

PHIO

Elevated riskNext report: Around Nov 12 (est.)

View price ↗

The short version

A company still losing money. Insiders are buying.

Going well

No debt reported

Watch out for

Losing money, losses are large next to sales

Money moves

An insider bought $10K of shares with their own money in the last 30 days
Institutions cut 3.2% from their holdings in the quarter ending June 2026 (10 bought, 12 sold)

Facts from SEC filings, not a recommendation.

The business over time

Last 12 quarters, from SEC filings

Profit, Jun '26

-$4.1M

Sep '23Tap a barJun '26

Last 12 months: -$12.9M.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/4Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-69.9%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissProfitable every yearSteady profits, not one good year.0 of 10 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$8.0M

Total debt: None; 0.00x equity
Current ratio: 17.81x; short-term assets / bills due
Free cash flow: -$8.0M

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: net margin 10%+, share count not growing, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 6

EPS: -$0.36; vs -$0.45
Free cash flow: -$4.0M
Share count: +142.3%; vs a year ago

Insider rating

Last 90 days

67Buying

2 insiders bought $17K
Ronald Todd Plott grew their stake 31.3%

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.6
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Distributing-3.2%

Institutions cut 3.2% from their holdings. 10 bought, 12 sold.

Shares held by institutions647K

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+196.5%

Cash runwayAt last year's cash burn

20 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

12M

Why elevated risk

Losing money, losses are large next to sales
About 20 months of cash left at its current burn
Share count growing 196.5% a year (dilution)

Earnings reports

Last 12

Next reportAround Nov 12 (est.)Estimated from the same quarter last year

Results filedAug 6
Results filedMay 7
Results filedMar 5
Results filedNov 13, 2025
Results filedAug 14, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

No offerings, red flags or new big holders. Clean record.

Insider trades

Open-market buys and sells, last 90 days

Bought$17K2 insiders

Sold$00 insiders

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Ronald Todd PlottDirector	Buy	10K	$1.03	$10K	42K	Sep 29Filing ↗
+31.3% of their holdings $1.03 to $1.04 across 2 trades Traded Sep 28 to Sep 29 Filed 1 day after
Patricia A BradfordDirector	Buy	7K	$1.01	$7K	64K	Sep 24Filing ↗
+11.3% of their holdings Filed 1 day after